Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024.
Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The immersive medical education software company is applying its medical-grade virtual reality platform to train surgeons.
The Canadian drugmaker was already considering putting itself up for sale after an FDA advisory committee voted against recommending approval for the drug, Brinavess, used for atrial fibrillation.
As many as two-thirds of glioblastoma patients don't respond to a central class of treatments due to a nifty DNA repair mechanism known as MGMT. DelMar Pharmaceuticals has a workaround that it hopes can extend the lives of patients in a meaningful way.
A three-month experiment in Canada with bimonthly text messages, a Web portal and home-based medical devices produced an average weight decrease of 3.5 pounds and a mean reduction in hemoglobin A1c levels from 7.41 to 6.77 percent in Type 2 diabetics.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
"Our tools are designed to work alongside existing programs to make human interactions more productive," said Michael Fergusson, Ayogo's founder and CEO.